NHMRC grant outcomes


CTC funding results

Congratulations to CTC research collaborators and CTC staff who have so far been successfully awarded $11.9 million in National Health and Medical Research Council (NHMRC) grants. Announced by federal Minister for Health, Tanya Plibersek, the medical research projects were funded in cancer, neonatal health, cardiovascular disease and health economics. Congratulations also to Emily Callander who was awarded an Early Career Fellowship Grant. Results of grant applications to Cancer Australia, Cancer Council and Heart Foundation will released later.

Read more about some of the grants awarded here:

ONCOLOGY

TOPGEAR- CIA Prof Leong was awarded $1,974,558 for the TOPGEAR clinical trial which will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in improving cure rates for stomach cancer

OUTBACK- CIA Professor Linda Mileshkin was awarded $1,472,782 for the OUTBACK international randomized phase III trial which will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.

SNAC1- CIA Prof Grantley Gill was awarded $366,663 for the SNAC1 study which will determine if sentinel node based management (a smaller operation removing a few lymph nodes) results in better quality of life and equivalent cure rates after 10 years follow-up compared with routine axillary clearance  (a larger operation removing many lymph nodes) in over 1000 women with early breast cancer recruited to this large scale randomized trial from 2001 to 2005.

 

NEONATAL

LIFT-CIA Prof Tarnow-Mordi was awarded $2,203,171 for the LIFT trial which aims to confirm if bovine lactoferrin, an inexpensive dairy protein, reduces death or major morbidity and increases total breast milk intake in 1,500 very low birthweight babies in neonatal intensive care unit.

 

CARDIOVASCULAR AND DIABETES

FIELD LIFE Study- CIA Prof Anthony Keech was awarded $621,134 for the FIELD LIFE study which will examine blood levels of a new class of regulatory molecules (called microRNAs), and of DNA damage to identify how they are linked to vascular risk factors, and heart, foot, eye and kidney damage in 2000 well-characterised Australians with type 2 diabetes from the FIELD Study. Genetic and environmental factors influence the risks of developing the blood vessel (vascular), eye and kidney complications of diabetes, but how extensively these factors interact is less well understood.

FIELD-CIA Prof Peter Meikle was awarded $1,071,754 for the lipidomic analysis of samples from the FIELD trial. It is known that patients with type 2 diabetes have abnormal blood lipids leading to an increased risk of cardiovascular disease.  This risk can be decreased by fenofibrate treatment.  However, not all patients show the same response to fenofibrate and so it is not clear who will benefit and who will not benefit from treatment.  In this project he will develop a test to identify those patients who respond to and benefit from fenofibrate treatment.  This will lead to the better outcomes for patients.

 

HEALTH ECONOMICS

Work&CareMOD -CIA Prof Deborah Schofield was awarded $609,900 in partnership with Carers Australia and Pfizer Australia to develop an economic model called Work&CareMOD which will provide information and will be a valuable tool in the assessment of the potential economic benefits of health interventions, not only to patients, but also those that extend to carers.

 

These projects represent research which aim to improve health outcomes in Australia and around the world.